Indeed, a decade ago, the first randomized, double-blind trials were conducted in order to examine the effect of COX2-inhibitors (Dexamethasone and Celecoxib) in prostate cancer patients [152,153]. This evidence concerns the gene PTGS2 and Familial prostate cancer.